Cytomegalovirus infection in solid-organ transplant recipients.
Conditions
Brief summary
Change in CMV Viral Load (log10 IU/mL) from Baseline to Week 3.
Detailed description
Change in the CMV-specific Immune Signature., Ability of baseline immune signature to stratify patients.
Interventions
DRUGEVEROLIMUS
DRUGMYCOPHENOLIC ACID
Sponsors
Centre Hospitalier Universitaire Vaudois
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in CMV Viral Load (log10 IU/mL) from Baseline to Week 3. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in the CMV-specific Immune Signature., Ability of baseline immune signature to stratify patients. | — |
Outcome results
None listed